Andrew S. Lim, MD

Assistant Professor of Clinical Radiation Oncology

Director of Brachytherapy

Image of Andrew S. Lim, MD
Is this your profile? Click to edit

Overview

Andrew Lim, MD, is a radiation oncologist at USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, who specializes in today’s most advanced forms of radiation therapy, including interstitial and surface brachytherapy, volumetric modulated arc therapy and stereotactic body radiation therapy.

At USC Norris, he serves as director of brachytherapy, a form of internal radiation therapy in which the radiation source is placed close to the cancer. Dr. Lim routinely treats prostate cancer, gynecologic cancers, sarcomas, skin cancer and metastatic cancers anywhere in the body.

His research interests focus on the development of artificial intelligence (AI) algorithms capable of integrating clinical, biochemical, genomics and radiologic data, with a goal of making personalized, probabilistic medical predictions. Dr. Lim has received several awards for his outstanding research and cancer care.

Away from work, he enjoys creating software tools that help people save time.

Awards

  • University of Alberta: The RJS and Ada Maude Wright Memorial Prize in Radiation Oncology, 2019
     – 2020
  • St. Francis Xavier University: Yogi Joshi Prize For Excellence in Physics, 2008
     – 2009
  • St. Francis Xavier University: Natural Sciences and Engineering Research Council of Canada Award, 2008
     – 2009

Education and Training

  • Western University, London, Ontario — MD — 06/2013 — Medicine
  • University of Alberta, Edmonton, Alberta — FRCPC — 06/2020 — Radiation Oncology
  • University of California, Los Angeles, Los Angeles — 06/2021 — Brachytherapy

Research Keywords

  • Informatics
  • Prostate Cancer
  • Brachytherapy
  • Artificial Intelligence
  • Cervix Cancer

Publications

  • Fragmentation of rest periods, astrocyte activation, and cognitive decline in older adults with and without Alzheimer’s disease. Alzheimers Dement. 2023 05; 19(5):1888-1900.. View in PubMed
  • Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022 Nov; 109(5):504-512.. View in PubMed
  • Injury patterns, management and outcomes of retroperitoneal haemorrhage caused by lower intercostal arterial bleeding at a level-1 trauma centre: A 10-year retrospective review. Emerg Med Australas. 2023 02; 35(1):56-61.. View in PubMed
  • Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022 Dec; 40(5):1020-1029.. View in PubMed
  • Impact of a policy to improve the management of oral medications when patients are fasting before a procedure: an interrupted time series analysis. BMJ Open Qual. 2022 05; 11(2).. View in PubMed
  • Protocol for SYNchronising Exercises, Remedies in GaIt and Cognition at Home (SYNERGIC@Home): feasibility of a home-based double-blind randomised controlled trial to improve gait and cognition in individuals at risk for dementia. BMJ Open. 2022 03 31; 12(3):e059988.. View in PubMed
  • Association between risk of obstructive sleep apnea, inflammation and cognition after 45 years old in the Canadian Longitudinal Study on Aging. Sleep Med. 2022 03; 91:21-30.. View in PubMed
  • High-Dose Rate Interstitial Spine Brachytherapy Using an Intraoperative Mobile Computed Tomography-Guided Surgical Navigation System. Oper Neurosurg. 2021 11 15; 21(6):507-515.. View in PubMed
  • Feasibility of a continuous, multi-sensor remote health monitoring approach in persons living with neurodegenerative disease. J Neurol. 2022 May; 269(5):2673-2686.. View in PubMed
  • Association of accelerometer-derived sleep measures with lifetime psychiatric diagnoses: A cross-sectional study of 89,205 participants from the UK Biobank. PLoS Med. 2021 10; 18(10):e1003782.. View in PubMed